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Summary P-glycoprotein gene (mdrl) amplification and expression were examined in murine leukaemia
P388/DX and melanoma B16VDXR cell lines, which exhibit a high level of resistance to a selecting agent,
doxorubicin, and express a multidrug-resistant phenotype because they are cross-resistant to multiple
cytotoxic drugs. The multidrug-resistant phenotype was obtained in different conditions of selection (in vivo
and in vitro for P388/DX and B16VDXR, respectively). In both multidrug-resistant cell lines, an increased
expression of P-glycoprotein gene (5 kb transcript detected in Northern blots) was observed and the level of P-
glycoprotein mRNA correlated with the degree of resistance. In addition, high molecular weight mRNAs
homologous to mdrl gene sequence were consistently detected only in P388/DX cells. Overexpression was
associated with a high level of gene amplification only in resistant melanoma cells, whereas it occurred in
P388/DX cells with a marginal increase in gene copy number. These results, suggesting that different genetic
mechanisms could be responsible for P-glycoprotein overexpression, emphasise the complexity of genetic
regulation that may affect tumour cell sensitivity to cytotoxic agents.
Several lines of evidence have indicated that increased
expression of a high molecular weight membrane glyco-
protein (P-glycoprotein) is responsible for multidrug-resistant
phenotypes (Riordan et al., 1985; Scotto et al., 1986). Using
cDNA clones encoding for P-glycoprotein, isolated from a
number of mammalian cells, it has been demonstrated that
P-glycoprotein genes (also termed mdrl genes) are amplified
and overexpressed in multidrug-resistant cell lines (Gros et
al., 1986a; Roninson et al., 1986). Nevertheless, multidrug
resistance in mammalian tumour cells is probably due to
multiple molecular mechanisms (Beck et al., 1987; Mirski et
al., 1987; Capranico et al., 1987).
Although gene amplification is reported to be the most
frequent mechanism of drug resistance (Schmike, 1984), the
genomic organisation and control of gene(s) involved in the
phenomenon of multidrug resistance has not been clearly
defined. In an attempt to throw light on the genetic basis of
multidrug resistance, we analysed mdrl gene amplification
and expression in murine doxorubicin-resistant melanoma
B16VDXR and leukaemia P388/DX cells. These cell lines
were selected since they exhibit a high level of resistance and
express a typical multidrug-resistant phenotype. Resistant
P388/DX and B16VDXR cell lines were developed
independently under different conditions of selection with in
vivo and in vitro doxorubicin treatments, respectively. P388/
DX, a well established cell line, showed an overall higher
degree of resistance than the B16VDXR cell line developed
more recently in vitro.
Materials and methods
Materials
Anthracyclines were obtained from Farmitalia-Carlo Erba
(Milan, Italy); vincristine sulphate from Lilly France SA
(Fegersheim, France); cisplatin, VP16 and VM26 from
Bristol Italiana (Latina, Italy). Restriction endonuclease
EcoRI was purchased from Bethesda Research Laboratories
(Eggenstein, West Germany); deoxycytidine-5' [Oa-32P]-
triphosphate (specific activity 3,000Cimmol-1) and
restriction endonucleases Hindlll and SalI from Amersham
International (Amersham, United Kingdom). Other
chemicals of the highest grade were supplied by Fluka
(Switzerland). Plasmid pcDR 1.3, containing a 1.3kb insert
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of mouse mdrl gene, was kindly provided by Dr P. Gros
(Gros et al., 1986b). After digestion of plasmid DNA with
restriction enzymes EcoRI and Sall, the 1.3kb fragment was
isolated by agarose gel and then used as a probe for
Northern and Southern blot hybridisations. A mouse f3-actin
probe was derived from plasmid pAL41 (Alonso et al.,
1986).
Murine tumour lines
Sensitive and resistant P388 cell lines were maintained in
mice by weekly i.p. transplantation, as already described
(Capranico et al., 1986). Melanoma B16VDXR cell line was
selected in vitro from cultured sensitive B16 cell line with
doxorubicin by stepwise increases in drug concentration
(Supino et al., 1986; Formelli et al., 1986). For cytotoxic
assay, in vitro cultures of P388 cells were established from
mouse ascites and, like melanoma B16 cells, were maintained
in RPMI 1640 medium (Flow Laboratories, McLean, VA,
USA). Drug cytotoxic activity was determined by the growth
inhibition assay; after 1 h exposure to drug, cells were
cultured in drug-free medium for 72h and then counted.
RNA extraction, Northern hybridisation and dot blotting
Leukaemic P388 and P388/DX cells were collected from
mouse ascites; erythrocytes were lysed by hypotonic
treatments. B16 and B16VDXR solid tumours were excised
from mice and cleaned of normal tissues. Total tumour
RNA was prepared by the LiCl-guanidine monothiocyanate
method according to Cathala et al. (1983). The poly(A)+
RNA fraction was separated on an oligo(dT)-cellulose
column (Pharmacia, Uppsala, Sweden). Northern gel electro-
phoresis and blot hybridisation were performed essentially
according to reported procedures (Maniatis et al., 1982).
Briefly, total or poly(A)+ RNAs were size fractionated on
denaturing 1% agarose gels; then gels were equilibrated in
20xSSC before overnight blotting to nitrocellulose (Bio-
Rad, Milan, Italy). The filters were baked at 80°C and then
prehybridised for at least 4h at 42°C in 50% formamid,
5 x SSC, 0.2% SDS, 5 x Denhardt solution, 50mM sodium
phosphate, pH 7.0, 250 igml- 1 of salmon sperm DNA.
Hybridisations were performed for 18-20h at 42°C with
denatured nick-translated mdrl or f,-actin probe (specific
activity 2-5xlO8c.p.m.pugDNA-1) in the presence of 10%
dextran sulphate. Final wash of filters was at 65°C in
0.1 x SSC, 0.1% SDS and autoradiography was at -70°C on
Amersham MP films, Rehybridisation of the same filters
with ,B-actin probe was carried out to determine the amount
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Figure 1 Northern blot analysis, Upper, total RNA (6pg, lanes
1-2) and poly(A)+RNA (2gg, lanes 3-6) were size fractionated
on agarose gels and transferred to nitrocellulose. The filters were
hybridised to the nick-translated 1.3kb mdrl probe. rRNA were
used as size markers. Samples are: P388 (lanes 1, 3); P388/DX
(lanes 2, 4); B16 (lane 5) and B16VDXR (lane 6). Lower, the
same blots rehybridised to a nick-translated f-actin probe to
compare the amount of RNA loaded in each lane.
of RNA loaded in each lane. Levels of mdrl gene expression
were determined in resistant cells by dot blot analysis of
poly(A)+ RNAs; the same dot blots were reprobed with 1l-
actin gene to normalise for the amount of RNA loaded in
each dot.
DNA extraction and Southern hybridisation
High molecular weight DNAs were extracted from tumour
samples essentially according to described techniques
(Maniatis et al., 1982). DNAs were then treated with
100pgml-1 of RNaseA (Boehringer Mannheim, Mannheim,
FRG) at 37°C for 2-4h, phenol-extracted and reprecipitated
with ethanol. Genomic DNAs were digested with restriction
endonucleases EcoRI or HindlIl. DNA fragments were size
fractionated in 0.7% agarose gels, run for 20 h at 1-
2Vcm-1, acid degraded (15min in 0.25M HCI), denatured
(30min in 0.5M NaOH, 1.5M NaCI), neutralised (45min in
0.5 M Tris-HCl, pH 7, 3M NaCl) and finally, blotted
overnight to nitrocellulose. Prehybridisation and
hybridisation conditions and final wash of filters were as
described for Northern blots. Copy number of mdrl gene
was calculated by intensities of bands in autoradiograms
estimated by a scanning densitometer and normalised for the
amount of DNA loaded in each lane reprobing the same
filter with a fi-actin probe.
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Figure 2 Southern blot analysis. Upper, genomic DNA (10 jg)
from P388 (lane 1), P388/DX (lane 2), B16 (lane 3) and
B16VDXR (lane 4) was digested with HindIII (a) or EcoRI (b)
restriction enzymes, electrophoresed on agarose gels and trans-
ferred to nitrocellulose. The blots were hybridised to the nick-
translated 1.3kb mdrl probe. Lower, rehybridisation of the same
filters with ,B-actin probe.
Results
Expression of P-glycoprotein gene
Analysis of P-glycoprotein gene expression in sensitive and
resistant P388 and B16 cells was carried out on total and
poly(A)+ RNA (Figure 1). High levels of mdrl gene
expression were observed in resistant cells, and a low level of
expression in sensitive cells. Rehybridisation of Northern
blots with a f-actin probe demonstrated that similar
quantities of RNA were present in each lane (Figure 1). As
expected (Gros et al., 1986a, b), mdrl probe detected a 5kb
transcript which was overexpressed in both P388/DX and
B16VDXR cells. However, under conditions of high
hybridisation stringency at least two mRNA of around 5.7
and 9.5 kb were also detected in autoradiograms of both
total and poly(A)+RNA from P388/DX cells, whereas such/
high molecular weight transcripts were not observed either in
P388 cells or in sensitive and resistant B16 cells.
Amplification of P-glycoprotein gene
To investigate whether the overexpressed gene was also
amplified, Southern blot analysis of mdrl gene was carried
out on genomic DNA digested with either EcoRI or HindlIl
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Table I Cross-resistance of murine tumour cell lines selected for resistance to doxorubicin
and mdrl gene amplification and expression
Relative resistancea Relative increaseb
Cell mdrl gene mdrl mRNA
line DX dmDR I-DX VP16 VM26 VCR cisPt amplification expression
P388/DX 703 46 16 28 55 615 3.7 3-4 87
B16VDXR 200 4.5 2.3 n.d.c n.d.c 138 0.4 40-50 38
aRatio between IDSO for resistant cells and ID for sensitive cells. ID50 values are drug
concentrations required for 50% cell growth inhibition following drug exposure for 1 h (P388)
or for 72h (B16). The relative resistance of melanoma cells to doxorubicin was similar
following 1 h and 72h exposure. DX, doxorubicin; dmDR, 4-demethoxydaunorubicin; I-DX,
4'-deoxy-4'-iodo-DX; VP16, etoposide; VM26, teniposide; VCR, vincristine; cisPt, cisplatin.
bLevel of amplification and expression in resistant cells were compared with those of sensitive
parental cells, to which a value of 1 was assigned. Levels of mdrl gene amplification were
determined by densitometry of Southern blot autoradiograms. mRNA levels were evaluated by
dot blot analysis of poly(A)+RNA. cn.d., not determined.
(Figure 2). P-glycoprotein gene amplification was evident in
B16VDXR cells as compared to B16 cells, whereas the
hybridisation signals from P388/DX cells were only slightly
more intense than those from P388 cells, indicating a much
lower degree of gene amplification in leukaemia compared
with melanoma cells. Therefore, the enhanced expression of
P-glycoprotein gene (Figure 1) appeared to be due to
increased gene copy number only in B16VDXR cells.
Moreover, rearrangements of mdrl gene did not occur in the
studied cell lines, as suggested by comparing the patterns of
bands in autoradiograms of EcoRI and HindlIl-restricted
DNAs (Figure 2).
Multidrug-resistant phenotypes and degree of overexpression
and amplification of P-glycoprotein gene
Table I summarises the resistance index for selected cytotoxic
agents and the lexls of amplification and overexpression of
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Figure 3 RNA dot blot analysis. Upper, poly (A') RNA (2jg)
from P388 (row 1), P388/DX (row 2), B16 (row 3) and B16VDXR
(row 4) was denatured in formaldehyde, serially diluted (1:2) and
loaded to nitrocellulose membrane using a dot-blotting apparatus
(Bio-Rad). The blot was hybridised to a nick-translated 1.3kb
mdrl probe. Lower, hybridisation of the same dot blot with a
nick-translated ,B-actin probe to confirm the amount of sample
added.
mdrl gene in the studied tumour cell lines. Patterns of cross-
resistance were similar in P388/DX and B16VDXR cells with
an overall higher degree of resistance for leukaemic cells
than for melanoma cells. Dot blot analysis of poly(A)+RNA
(Figure 3) demonstrated that levels of overexpression of P-
glycoprotein gene paralleled the degree of multidrug
resistance, since mdrl gene was 87- and 38-fold more
expressed in P388/DX and B16VDXR cells, respectively,
than in the sensitive counterparts. On the contrary, analysis
of Southern autoradiograms with a scanning densitometer
showed that gene copy number was markedly increased only
in resistant melanoma cells.
Discussion
The mouse mdrl DNA sequence used in this study is derived
from plasmid pcDR 1.3, which contains a 1.3kb fragment of
a full length mdr cDNA capable of conferring a multidrug-
resistant phenotype (Gros et al., 1986b). Our findings show
that mdrl gene is overexpressed in P388/DX and B16VDXR
cells, strongly suggesting that P-glycoprotein may contribute
to the high degree of resistance of these two resistant cell
lines (Table I). However, genetic bases underlying the
enhanced expression are likely to be different, since an
elevated copy number of mdrl gene was present in the
melanoma drug-resistant cell line, whereas gene amplification
occurred only at very low levels in P388/DX cells. Since high
molecular weight mdrl mRNAs were consistently observed
in P388/DX but not in P388 cells (Figure 1), it is likely that
the process of gene transcription is modified in these
multidrug-resistant cells. The precise nature of this alteration
is as yet unknown. An insertion of a strong enhancer/
promoter sequence near the gene might allow an increased
gene expression in the absence of gene amplification.
However, this possibility seems unlikely, since gene re-
arrangements were not detected in either P388/DX or
B16VDXR cells as compared to sensitive cells (Figure 2),
using two restriction endonucleases. Thus, activation of the
P-glycoprotein gene might be due to mutations in the coding
and/or regulatory regions of the mdrl gene, or to an
increased stability of mRNA caused by modifications of
post-transcriptional events or, even, to a depression
mechanism of a normally repressed state of the mdrl genes
in sensitive mammalian cells. At the present time, none of
these and other possibilities is favoured and further studies
and cloning of the P-glycoprotein gene from the P388/DX
cell line will be useful to clarify these aspects.
A similar dissociation of gene amplification and expression
has been also described by Shen et al. (1986) in cultured
human multidrug-resistant cell lines. However, it must be
noted that this dissociation is usually observed in the early
stages of development of drug resistance. Acquisition of high
levels of multidrug resistance usually results also in geneMULTIDRUG-RESISTANT MURINE CELLS 685
amplification (Bradley et al., 1988). This is not the case of
P388/DX, characterised by a high degree of resistance. In
contrast, the high level of gene amplification found in
B16VDXR reflects a more commonly described
phenomenon, although this line has been recently developed.
These observations favour the hypothesis that alterations at
transcription level are a critical step in the development of
multidrug resistance.
Relevant to this point is the observation that a revertant
cell line of a multidrug-resistant human leukaemia has
shown greatly decreased P-glycoprotein mRNA levels,
without a corresponding loss of amplified DNA (Sugimoto
et al., 1987). Altogether, these findings indicate that mdrl
gene can be activated or inactivated at the level of
transcription, regardless of gene copy number in the cellular
genome, thus emphasising the complexity of genetic
regulation that may affect cell sensitivity to cytotoxins. In
general, the study of multidrug resistance in P388/DX cells
has revealed that complex biochemical and genetic
mechanisms are involved in cell protection against cyto-
toxins. In particular, molecular alterations at a nuclear level
are, at least in part, responsible for the high degree of drug
resistance of these cells (Capranico et al., 1986, 1987).
Taken together with previous observations, these results
further support the idea that multidrug-resistant phenotypes
may arise from multiple molecular and genetic alterations in
mammalian cancer cells (Capranico et al., 1987; Beck et al.,
1987). The relative role of these molecular modifications
might differ markedly among different tumour cell lines
depending on several factors including the origin of the
multidrug-resistant tumour line (Hill & Bellamy, 1984). It
still remains to be determined if the manner in which
resistant cells are obtained (i.e. in vivo or in vitro selection
with doxorubicin) can influence the genetic mechanism of
antitumour drug resistance.
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